Subscribe To
Viracta therapeutics announces first clinical response in epstein-barr virus-positive (ebv+) solid tumor setting and outlines key 2023 clinical objectives
Partial response (PR) observed in third dose level of the Phase 1b dose escalation study of Nana-val in EBV+ recurrent/metastatic (R/M) nasopharyngeal...
January 8, 2023, 6:00 pm
Roche's (rhhby) cancer drug glofitamab gets fda priority review
The FDA accepts and grants priority review to Roche's (RHHBY) biologics license application for glofitamab to treat ...
January 6, 2023, 12:02 pm
Molecular partners presents new preclinical data supporting its mp0533 darpin t-cell engager for the treatment of aml
New data indicates potential to expand the therapeutic window and improve safety compared to existing T-cell engagers Tri-specific T-cell engager resu...
December 13, 2022, 12:00 am
Metafora partner wugen to present data supporting clinical development of wu-nk-101 for relapsed / refractory aml at the american society of hematology's (ash) 64th annual meeting
PARIS, France & NEW ORLEANS, La.--( BUSINESS WIRE )--METAFORA biosystems announces that its partner Wugen presented data supporting clinical developme...
December 12, 2022, 3:23 pm
Adicet bio shares fall as it shares clinical data about its car-t treatment candidate
Adicet Bio's Inc. ACET, -13.13% stock tumbled about 38% in premarket trading on Monday after the company shared data from a Phase 1 clinical trial eva...
December 12, 2022, 8:47 am
Harpoon therapeutics presents updated interim results at ash 2022 for novel t cell engager hpn217 in relapsed/refractory multiple myeloma
Clinically active across a wide dose range (2.15 to 24 mg) in a Phase 1 trial of heavily pretreated patients with ...
December 11, 2022, 3:00 pm
Kura oncology presents updated clinical data from komet-001 trial of menin inhibitor ziftomenib at american society of hematology annual meeting
– 30% CR rate at 600 mg in 20 patients with relapsed/refractory NPM1-mutant AML –– Low frequency ...
December 10, 2022, 3:30 pm
Sutro biopharma announces presentation of stro-002 data from the compassionate use program in pediatric patients with relapsed/refractory cbf/glis aml at ash 2022
– A total of 17 pediatric patients were treated with STRO-002 on a compassionate use basis; eight patients achieved complete remission, of which sev...
December 10, 2022, 3:30 pm
Arcellx flies on $325m deal with gilead's kite for multiple myeloma treatment
Arcellx shares soared in early trade after the clinical-stage biotechnology company announced a global strategic collaboration with Gilead Sciences' K...
December 9, 2022, 11:42 am
Syndax's (sndx) leukemia drug gets fda breakthrough therapy tag
The FDA bestows a Breakthrough Therapy designation to Syndax's (SNDX) revumenib for treating patients with rel...
December 6, 2022, 9:47 am
Poseida therapeutics to present early data from phase 1 trials of p-muc1c-allo1 and p-bcma-allo1 at esmo immuno-oncology 2022 annual congress
P-MUC1C-ALLO1 and P-BCMA-ALLO1 were well tolerated, with no dose-limiting toxicities (DLTs), cytokine release syndrome (CRS), graft vs host disease (G...
December 6, 2022, 6:00 am
Beam up as fda lifts clinical hold on the ind for beam-201
The FDA lifts the clinical hold on BEAM's investigational new drug application for BEAM-201 to treat relapsed<...
December 5, 2022, 12:48 pm
Rigel (rigl) up on fda nod to blood cancer drug rezlidhia
The FDA approves Rigel's (RIGL) Rezlidhia (olutasidenib) for treating relapsed/refractory acute myeloid...
December 2, 2022, 2:18 pm
Rigel pharmaceuticals (rigl) stock soars on fda approval news
Rigel Pharmaceuticals (NASDAQ: RIGL ) stock is heading higher on Friday after getting approval from the U.S. Food and Drug Administration (FDA) for it...
December 2, 2022, 11:17 am
Abbvie (abbv) bla for epcoritamab gets fda priority tag
The FDA grants priority review status to AbbVie's (ABBV) BLA for epcoritamab for the relapsed/refractor...
November 22, 2022, 7:32 am
Autolus therapeutics: near-term catalyst plus several bio deals could shift momentum
Results from the pivotal FELIX phase 2 clinical study using obe-cel for the treatment of patients with relapse...
November 16, 2022, 6:21 am
Harpoon therapeutics to present interim results from phase 1 clinical trial of t cell engager hpn217 at the 64th ash annual meeting and exposition
Updated interim results from Phase 1 clinical trial of HPN217 in heavily pretreated patients with relapsed...
November 3, 2022, 9:09 am
Innate pharma to present lacutamab ptcl phase 1b design and anket™ platform at esmo 2022
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today an...
September 5, 2022, 1:00 am
Day one biopharmaceuticals: recent strong data, and major catalysts ahead
Day One Biopharmaceuticals declared strong data in relapsed glioma in June. The company has strong cash...
September 4, 2022, 12:17 pm
Caribou biosciences: potential to change car-t landscape
Proof of concept established using CRISPR allogeneic CAR-T CB-010 for the treatment of patients with relapsed<...
August 1, 2022, 2:19 pm